- DKK18.31bn
- DKK16.09bn
- DKK6.24bn
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
Brief: Bavarian Nordic Awarded Multi-Year Vaccine Contract By UK Government
Bavarian Nordic donates 75,000 mpox vaccine doses to global emergency stockpile
Brief: Bavarian Nordic Donates To Global Mpox Emergency Stockpile
Bavarian Nordic jumps as travel health unit drives outlook hike
European shares dip as banks hit over 3-month low, oil prices weigh
Brief: Bavarian Nordic Raises Revenue, EBITDA Margin Forecasts
Brief: Bavarian Nordic Appoints Tarja Stenvall As CEO
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
Bavarian Nordic jumps on Q2 beat, outlook hike amid soaring vaccine sales
Vaccine maker Bavarian Nordic Q2 revenue rises on Travel Health growth
Brief: Bavarian Nordic Q2 EBITDA DKK 925 Million
Brief: Bavarian Nordic Now Expects 20026 Revenue At Upper End Of Previous Guidance Range
Brief: Bavarian Nordic To Launch Buy-Back Of Up To DKK 750 Million
Brief: Bavarian Nordic Receives European Commission Approval Of Mpox/Smallpox Vaccine For Children Aged 2 To 12
Brief: Bavarian Nordic's Chikungunya Vaccine Submitted For Regulatory Approval In Brazil
Brief: Bavarian Nordic Completes Share Buy-Back Program At About Dkk 150 Million
Brief: Bavarian Nordic Receives Health Canada Approval For Chikungunya Vaccine
Brief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract